|
Our technology provides a platform from which multiple drugs (therapeutic peptides, fusion proteins, signal blocking antibodies, and small molecule agonists/antagonists) can be commercialized for the treatment of a wide variety of human diseases. Because inflammation is at the source of every human disease, our discovery and the description of it's immunological mode of action has profound implications to medical science.
Our drug development program is devoloping our lead drug candidate as an injectable therapeutic for the adjunctive treatment of antibiotic resistant hospital acquired skin and soft tissue infections. We are also developing an oral formulation for use in community acquired infections. Subsequent therapeutic classes of drugs that result from our platform include a mucosal adjuvant for a new influenza vaccine. Other drug targets include monoclonal antibodies (mAb's) as signal blocking drugs, as well as small molecule agonists and antagonists for the treatment of chronic idiopathic diseases. This platform and the resulting therapeutic classes of drugs with their indications for use are depicted in the diagram.
|
| Drug Development Pipeline |
|
Our
lead drug
candidates are therapeutic peptides that are derived from a newly discovered regulator of the innate arm of the immune response. Our lead indication for human use is the treatment/prevention of hospital acquired infections (nosocomial infections). Other indications currently under development include a vaccine adjuvant that stimulates a mucosal immune response, anti-viral drugs, an agent that enhances wound healing, and new therapeutics for the chronic idiopathic diseases.
We are conducting preclinical safety studies in preparation for filing an IND
with the FDA for the use of our lead drug candidate in treating MRSA skin and soft-tissue infections.
|
|
